24 research outputs found
Amoxicillin pharmacokinetics in preterm infants with gestational ages of less than 32 weeks
The multiple-dose pharmacokinetics of amoxicillin (AM [administered twice
daily in a 25-mg/kg of body weight intravenous dose]) in 17 preterm
infants (11 males; gestational age, 29 +/- 1.9 weeks; birth weight, 1,175
+/- 278 g) were evaluated on day 3 of life. Blood samples were collected
from an arterial catheter at 0, 0.5, 1, 2, 4, 8, and 12 h after the
intravenous dose. A high-performance liquid chromatography method was used
to determine AM concentrations in serum. AM pharmacokinetics followed a
one-compartment open model. The glomerular filtration rates of all
patients were simultaneously studied by means of the 24-h continuous
inulin infusion technique. The elimination half-life, apparent volume of
distribution, and total body clearance of AM (mean +/- standard deviation)
were 6.7 +/- 1.7 h, 584 +/- 173 ml, and 62.4 +/- 23.3 ml/h, respectively.
The mean (+/- standard deviation) AM peak and trough levels were 53.6 +/-
9.1 and 16.0 +/- 4.9 mg/liter, respectively. All infants had a serum
trough level above 5 mg/liter. The total body clearance and apparent
volume of distribution of AM and the clearance of inulin increased
significantly with increasing gestational age. The total bod
Once-daily versus twice-daily administration of ceftazidime in the preterm infant
Ceftazidime pharmacokinetics in 28 preterm infants (gestational ages, 25.6
to 31.9 weeks) were studied on day 3 of life. Patients with suspected
septicemia were randomized on day 1 of life in two groups. One group (n =
13) was administered 25 mg of ceftazidime per kg of body weight once
daily, and the other (n = 15) was given 25 mg of ceftazidime per kg twice
daily. Both groups also received 25 mg of amoxicillin per kg twice daily.
Blood samples were collected on day 3 of life with an arterial catheter at
0, 0.5, 1, 2, 4, 8, and 12 h after an intravenous bolus injection. An
additional blood sample was taken at 24 h from the group dosed once a day.
High-performance liquid chromatography was used to determine serum
ceftazidime concentrations. The pharmacokinetics of ceftazidime were best
described by using a one-compartment model. The half-life for the
elimination of the drug from serum, apparent volume of distribution, total
body clearance of ceftazidime, and inulin clearance were not significantly
different for both groups. The ceftazidime/inulin clearance ratio was 0.72
for both groups. However, trough concentrations in serum for the
twice-daily group were significantly (P < 0.001) higher (42.0 +/- 13.4
mg/liter) than those for the once-daily group (13.1 +/- 4.7 mg/liter). The
latter concentrations were all still substantially higher than the MIC of
ceftazidime for major neonatal pathogens. We conclude that the currently
recommended dosage of 25 mg of ceftazidime per kg twice daily for preterm
infants with gestational ages below 32 weeks may be adjusted during the
first days of life to one daily dose at 25 mg/kg, provided that for the
empirical treatment of septicemia, amoxicillin at 25 mg/kg is also given
twice daily
Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625
CB1 antagonists such as AVE1625 are potentially useful in the treatment of obesity, smoking cessation and cognitive impairment. Proof of pharmacological action of AVE1625 in the brain can be given by antagonising the effects of delta-9-tetrahydrocannabinol (THC), a CB1/CB2 agonist. Inhibition of THC-induced effects by AVE1625 was observed on Visual Analogue Scales 'alertness', 'feeling high', 'external perception', 'body sway' and 'heart rate'. Even the lowest dose of AVE1625 20 mg inhibited most of THC-induced effects. AVE1625 did not have any effect on psychological and behavioural parameters or heart rate by itself. After THC and AVE1625 administration, changes on electroencephalography were observed. This study shows a useful method for studying the effects of CB1 antagonists. AVE1625 penetrates the brain and antagonises THC-induced effects with doses at or above 20 mg.Stress-related psychiatric disorders across the life spa
Saccadic peak velocity and EEG as end-points for a serotonergic challenge test.
We previously reported that a single dose of the serotonin receptor agonist meta-chlorophenylpiperazine increased the peak velocity of saccadic eye movements and decreased low-frequency electroencephalographic activity. METHODS: We administered a single dose of the serotonin releaser dexfenfluramine in a double blind, placebo controlled randomised cross-over design and measured saccadic eye movements and EEG every hour up to 6 h. Subjects were 62 males (18-30 years) with a history of no, moderate or heavy use of ecstasy tablets. RESULTS: Dexfenfluramine increased saccadic peak velocity and decreased alpha, delta and theta electroencephalographic activity, the latter predominantly in heavy users of ecstasy. CONCLUSIONS: This study supports the idea that saccadic peak velocity and EEG can be useful endpoints of a serotonergic challenge. This could be an important anatomical extension of these end-points, which until now were limited to the effect on hypothalamic serotonergic projections
Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol
Central Nervous System (CNS) effects of talnetant, an NK-3 antagonist in development for schizophrenia, were compared to those of haloperidol and placebo. The study was randomised, double-blind, three-way crossover of talnetant 200 mg, haloperidol 3 mg or placebo. Twelve healthy males participated and EEG, saccadic and smooth pursuit eye movements, adaptive tracking, body sway, finger tapping, hormones, visual analogue scales (VAS) for alertness, mood and calmness and psychedelic effects, left/right distraction task, Tower of London and Visual and Verbal Learning Task were assessed. Haloperidol showed (difference to placebo; 95% CI; p-value) decreases in EEG alpha power (-0.87microV; -1.51/-0.22; p = 0.0110), saccadic inaccuracy (2.0%; 0.5/3.6; p = 0.0133), smooth pursuit eye movements (-7.5%; -12.0/-3.0; p = 0.0026), adaptive tracking (-3.5%; -5.4/-1.7; p = 0.0009), alertness (-6.8 mm; -11.1/-2.4; p = 0.0039), negative mood (-4.6 mm; -8.6/-0.6; p = 0.0266), the ability to control thoughts (1.2 mm; 0.2/2.3; p = 0.0214), and an increase of serum prolactin (ratio 4.1; 3.0/5.6; p < 0.0001). Talnetant showed decreased alpha power (-0.69 muV; -1.34/-0.04; p = 0.0390), improved adaptive tracking (1.9%; 0.1/3.7; p = 0.0370) and reduced calmness on VAS Bond and Lader (-4.5 mm; -8.0/-1.0; p = 0.0151). Haloperidol effects were predominantly CNS-depressant, while those of talnetant were slightly stimulatory. The results suggest that talnetant penetrates the brain, but it remains to be established whether this dose is sufficient and whether the observed effect profile is class-specific for NK3-antagonists.Stress-related psychiatric disorders across the life spa
A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema
BACKGROUND: Hereditary angioedema (HAE) is a congenital disorder with recurrent attacks of localized swelling of submucosal tissue, subcutaneous tissue, or both caused by a deficiency of the plasma protein C1 inhibitor (C1 esterase inhibitor [C1INH]). OBJECTIVE: We sought to evaluate the effects of recombinant human C1INH (rhC1INH) isolated from the milk of transgenic rabbits in 12 asymptomatic patients with HAE. METHODS: rhC1INH was intravenously administered at doses of 6.25 to 100 U/kg on 2 occasions. RESULTS: rhC1INH appeared safe and was well tolerated. The course of functional C1INH in plasma showed a full initial recovery (dose-normalized maximum concentration of about 0.02 U/mL/U/kg) and a dose-dependent clearance of rhC1INH. After infusion of rhC1INH at 100 U/kg, a clearance of approximately 13 mL/min, a half-life of approximately 3 hours, and a volume of distribution of approximately 3 L were observed. Infusion at this dose led to functional C1INH levels in plasma of at least twice the normal level for about 2 hours and greater than 0.4 U/mL for about 9 hours. rhC1INH displayed dose-dependent biologic activity by increasing the C4 level, which was about 2-fold at 12 hours after rhC1INH at 100 U/kg, and decreasing levels of cleaved C4. CONCLUSION: The observed safety profile and biologic activity of rhC1INH warrants further clinical studies to assess its efficacy in treating HAE attack
Assessing the Probability of Drug-Induced QTc-Interval Prolongation During Clinical Drug Development
The effects of TPA023, a GABA(A)alpha(2,3) subtype-selective partial agonist, on essential tremor in comparison to alcohol
Stress-related psychiatric disorders across the life spa